Home Daily Stock Opinions and Ratings Knight Therapeutics (GUD-T)

Trending stocks today

Lennar Corp. Bunge Ltd. United Therapeutics Corp. Metro Inc (A) Rogers Communications (B) Procter & Gamble AbbVie Inc. Spirit Airlines Inc. Intel Visa Inc. Applied Materials AutoCanada Inc. Alimentation Couche-Tard Fortis Inc. MONDELEZ INTERNATIONAL INC Common Stock S&P Global Inc Alphabet Inc Jacobs Engineering Group Inc. Visa Inc.

Knight Therapeutics (GUD-T)

131 watching

TSE:GUD

4.43
0.03 (0.68%) 1d
Sep 22, 2023, 8:00 pm
0
HOLD

Knight Therapeutics(GUD-T)

13/01/2023
Knight Therapeutics

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable. Unlock Premium - Try 5i Free

0
Stockchase Insights
$5.250
Unknown
UnlockRating
HOLD

Knight Therapeutics(GUD-T)

12/12/2022
Knight Therapeutics
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. I Good Q2 results but weaker bottom line. Growth potential remains. No dividend to keep investors patient. Valuation arguably more attractive today.
0
Stockchase Insights
$5.280
Unknown
UnlockRating
BUY

Knight Therapeutics(GUD-T)

23/11/2022
Knight Therapeutics
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable.
0
Stockchase Insights
$5.220
Unknown
UnlockRating
HOLD

Knight Therapeutics(GUD-T)

30/09/2022
Knight Therapeutics
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable. Rating maintained at ‘B'.
0
Stockchase Insights
$5.310
Unknown
UnlockRating
HOLD

Knight Therapeutics(GUD-T)

21/09/2022
Knight Therapeutics
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Sales 30% ahead of estimates. M&A pipeline active, investors expect more. COVID helped sales growth. Impressive quarter results.
0
Stockchase Insights
$5.520
Unknown
UnlockRating
WAIT

Knight Therapeutics(GUD-T)

07/09/2021
Knight Therapeutics
The superstar CEO with a great track record raised a pile of cash, but didn't do anything with it. He had a short position on this 6 months ago, and covered that recently. GUD has poor price momentum, though little volatility, and no real earnings. PE is high, though a strong balance sheet. This is a show-me story.
0
Jason Mann
$5.520
No
UnlockRating
HOLD

Knight Therapeutics(GUD-T)

06/08/2021
Knight Therapeutics

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Although the stock has not moved, the basic thesis has not changed. There is some weakness in South America which has impacted their acquisition. With no dividend, there is an opportunity cost to the stock, but outlook remains intact. Unlock Premium - Try 5i Free

0
Stockchase Insights
$5.170
Unknown
UnlockRating
WEAK BUY

Knight Therapeutics(GUD-T)

01/06/2021
Knight Therapeutics
The CEO has a great track record, but he's been slow to deploy capital which the market doesn't like. He bought a company in Brazil, so there's currency risk. Hold on and be patient. Short-term, investors are frustrated, but long term this should be fine. The CEO is sitting on a lot of cash.
0
Jason Del Vicario
$5.330
Unknown
UnlockRating
BUY

Knight Therapeutics(GUD-T)

21/04/2020
Knight Therapeutics

Brilliant CEO. It's sitting on a lot of cash, because of the CEO who is patient and will slowly build Knight. He's not chasing acquisitions to spend cash.

0
Lorne Steinberg
$7.540
No
UnlockRating
HOLD

Knight Therapeutics(GUD-T)

26/02/2020
Knight Therapeutics
A frustrating name. They have a great management team. For a couple of years, he has been waiting for the execution of a big deal that finally came about. The market is selling it down and he is not really sure why. He thinks investors are just selling it off with the uncertainty in the market currently. It trades at 0.7 times book value. He still thinks things are fine.
0
Ryan Modesto
$7.070
Unknown
UnlockRating
BUY

Knight Therapeutics(GUD-T)

30/12/2019
Knight Therapeutics
He still likes it. There is a changeover in the investor base. A lot of people were hiding in it for cash and book value, and now investors are interested in the growth so there is a changeover. He likes it here.
0
James Hodgins
$7.610
Owned
UnlockRating
WEAK BUY

Knight Therapeutics(GUD-T)

12/12/2019
Knight Therapeutics
All their cash is going to be deployed in a patient, diversified manner. He views it more like a venture fund and so it is hard for him to analyze all of their businesses. It could be held for the long run.
0
Stephen Takacsy, B. Eng, MBA
$7.570
No
UnlockRating
DON'T BUY

Knight Therapeutics(GUD-T)

25/11/2019
Knight Therapeutics
It grows by acquisition. The company is trading at 36x forward earnings, which is quite expensive. There aren’t a lot of analysts covering this right now.
0
Robert McWhirter
$7.720
No
UnlockRating
TOP PICK

Knight Therapeutics(GUD-T)

07/11/2019
Knight Therapeutics
They finally did that large acquisition that people have been expecting. They will still have some cash after the deal. Markets will take some time to come to terms with how this company will look. He does not think this company is done with acquisitions.
0
Ryan Modesto
$8.340
Owned
UnlockRating
BUY

Knight Therapeutics(GUD-T)

16/08/2019
Knight Therapeutics

His biggest holding. They have $6.85 in tangible book value, mostly cash. The CEO may buy Paladin or Cipher Pharmaceuticals. Be patient for this deal. It'll be accretive.

0
James Hodgins
$7.800
Owned
UnlockRating
Showing 1 to 15 of 98 entries
Next PageNext Page

Knight Therapeutics(GUD-T) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 4

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 5

Stockchase rating for Knight Therapeutics is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Knight Therapeutics(GUD-T) Frequently Asked Questions

What is Knight Therapeutics stock symbol?

Knight Therapeutics is a Canadian stock, trading under the symbol GUD-T on the Toronto Stock Exchange (GUD-CT). It is usually referred to as TSX:GUD or GUD-T

Is Knight Therapeutics a buy or a sell?

In the last year, 5 stock analysts published opinions about GUD-T. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Knight Therapeutics.

Is Knight Therapeutics a good investment or a top pick?

Knight Therapeutics was recommended as a Top Pick by on . Read the latest stock experts ratings for Knight Therapeutics.

Why is Knight Therapeutics stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Knight Therapeutics worth watching?

5 stock analysts on Stockchase covered Knight Therapeutics In the last year. It is a trending stock that is worth watching.

What is Knight Therapeutics stock price?

On 2023-09-22, Knight Therapeutics (GUD-T) stock closed at a price of $4.43.

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Get Access To Watchlist

Latest Buy Signals

ZBRA-QZebra Technologies Corp
Zebra Technologies Corp
$227.15
-1.53 (-0.68%)
AMD-QAdvanced Micro Devices
Advanced Micro Devices
$96.20
0.09 (0.09%)
ZTS-NZoetis Inc
Zoetis Inc
$176.68
0.05 (0.03%)
CAT-NCaterpillar
Caterpillar
$273.06
1.03 (0.38%)
LEN-NLennar Corp.
Lennar Corp.
$113.50
0.37 (0.32%)
Advertising

Today's Top Picks

V-NVisa Inc.
Visa Inc.
$235.08
-1.53 (-0.66%)
JEC-NJacobs Engineering Group Inc.
Jacobs Engineering Group Inc.
$85.84
0.00 (0.00%)
GOOG-QAlphabet Inc
Alphabet Inc
$131.25
-0.11 (-0.08%)
SPGI-NS&P Global Inc
S&P Global Inc
$371.69
-0.62 (-0.17%)
MDLZ-QMONDELEZ INTERNATIONAL INC Common Stock
MONDELEZ INTERNATIONAL INC Common Stock
$70.43
-0.28 (-0.40%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

NVST-NEnvista Holdings
Envista Holdings
$27.83
0.27 (0.96%)
AMT-NAmerican Tower
American Tower
$166.21
-3.11 (-1.91%)
F-NFord Motor
Ford Motor
$12.43
0.23 (1.82%)
T-NAT&T
AT&T
$15.12
-0.19 (-1.27%)
COP-NConocoPhillips
ConocoPhillips
$119.16
0.09 (0.08%)

Most Recent Experts

Reid

Gordon Reid

GoodReid Investment Counsel

Stockchase

Stockchase Insights

5i Research

Weiss

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Talkington

Bryn Talkington

Requisite Capital Management

Saccocia

Shannon Saccocia, CIO, Boston Private

Boston Private

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.